Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026)
Palvella Therapeutics (PVLA) reported Retained Earnings of $95000.0 for Q1 2026, up 100.09% year-over-year from $47477.9 in Q1 2025, and up 100.07% on a QoQ basis from -$135.4 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Retained Earnings data on file, last reported at $95000.0 in Q1 2026.
- Quarterly Retained Earnings rose 100.09% year-over-year to $95000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95000.0 (up 100.09% YoY) and the FY2025 annual result came in at -$135.4 million, down 4515100.0% from the prior year.
- Retained Earnings grew to $95000.0 in Q1 2026 per PVLA's latest filing, from -$135.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $953000.0 in Q1 2022 and bottomed at -$326.3 million in Q3 2024.
- The 5-year median for Retained Earnings is -$129.1 million (2025), against an average of -$162.4 million.
- The widest annual swing landed in 2022, when Retained Earnings surged 391.24%; it then plunged 4515100.0% in 2025.
- Tracing PVLA's Retained Earnings over 5 years: stood at -$254000.0 in 2022, then plunged by 33.46% to -$339000.0 in 2023, then surged by 100.88% to $3000.0 in 2024, then sank by 4515100.0% to -$135.4 million in 2025, then surged by 100.07% to $95000.0 in 2026.
- Per Business Quant, the three latest PVLA Retained Earnings figures stand at $95000.0 (Q1 2026), -$135.4 million (Q4 2025), and -$122.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 95,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95,000.00 |
| Dec 31, 2025 | -135.45 Mn |
| Sep 30, 2025 | -122.70 Mn |
| Jun 30, 2025 | -111.40 Mn |
| Mar 31, 2025 | -101.90 Mn |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | -326.30 Mn |
| Jun 30, 2024 | -323.45 Mn |
| Mar 31, 2024 | -319.86 Mn |
| Sep 30, 2023 | -339,000.00 |
| Jun 30, 2023 | -299.60 Mn |
| Mar 31, 2023 | -303.60 Mn |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -282.30 Mn |
| Jun 30, 2022 | -272.60 Mn |
| Mar 31, 2022 | 953,000.00 |
| Dec 31, 2021 | -257.14 Mn |
| Sep 30, 2021 | 616,000.00 |
| Jun 30, 2021 | -231.10 Mn |
| Mar 31, 2021 | 194,000.00 |
| Dec 31, 2020 | -295,000.00 |
| Sep 30, 2020 | -782,000.00 |
| Jun 30, 2020 | -1.06 Mn |
| Mar 31, 2020 | -1.23 Mn |
| Dec 31, 2019 | -174.18 Mn |
| Sep 30, 2019 | -173.41 Mn |
| Jun 30, 2019 | -2.71 Mn |
| Mar 31, 2019 | -2.06 Mn |
| Dec 31, 2018 | -147.07 Mn |
| Sep 30, 2018 | -135.38 Mn |
| Jun 30, 2018 | -129.23 Mn |
| Mar 31, 2018 | -129.03 Mn |
| Dec 31, 2017 | -120.31 Mn |
| Sep 30, 2017 | -127.80 Mn |
| Jun 30, 2017 | -2.09 Mn |
| Mar 31, 2017 | -1.45 Mn |
| Dec 31, 2016 | -1.50 Mn |
| Sep 30, 2016 | -1.33 Mn |
| Jun 30, 2016 | -1.33 Mn |
| Mar 31, 2016 | -84.03 Mn |
| Dec 31, 2015 | -79.87 Mn |
| Sep 30, 2015 | -1.15 Mn |
| Jun 30, 2015 | -1.34 Mn |
| Mar 31, 2015 | -1.45 Mn |
| Dec 31, 2014 | -65.81 Mn |
| Sep 30, 2014 | 29,904.00 |
| Jun 30, 2014 | 15,986.00 |
| Mar 31, 2014 | -9,778.00 |
| Dec 31, 2013 | -55.96 Mn |
| Jun 30, 2013 | -274.00 |